(Abst.) Safety and efficacy of autologous HSCT for MS in Norway on: December 14, 2019, 04:59:16 pm #1 This is a small study (30 patients) but the finding that some patients had amenorrhea lasting more than 12 months and ovarian failure would be a concern.From PubMed (December 14, 2019), "Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway": Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway - PubMed HSCT in MS is an effective and relatively safe treatment option, with few serious complications and no mortality in Norway, so far. However, long-term adverse event with amenorrhea is a common prob... PubMed · ncbi.nlm.nih.gov Logged MS Speaks--online for 20 yearsSPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) 12/16/20 - 3/16/24.
